- Home
- AUPH vs CENTA Comparison
AUPH vs CENTA Comparison
Compare AUPH & CENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- CENTA
- Stock Information
- Founded
- AUPH 1993
- CENTA 1955
- Country
- AUPH Canada
- CENTA United States
- Employees
- AUPH N/A
- CENTA N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- CENTA Consumer Specialties
- Sector
- AUPH Health Care
- CENTA Consumer Discretionary
- Exchange
- AUPH Nasdaq
- CENTA Nasdaq
- Market Cap
- AUPH 1.6B
- CENTA 1.8B
- IPO Year
- AUPH 1999
- CENTA 1993
- Fundamental
- Price
- AUPH $13.17
- CENTA $28.07
- Analyst Decision
- AUPH Strong Buy
- CENTA Buy
- Analyst Count
- AUPH 2
- CENTA 4
- Target Price
- AUPH $13.00
- CENTA $36.67
- AVG Volume (30 Days)
- AUPH 1.3M
- CENTA 335.9K
- Earning Date
- AUPH 11-04-2025
- CENTA 11-24-2025
- Dividend Yield
- AUPH N/A
- CENTA N/A
- EPS Growth
- AUPH N/A
- CENTA N/A
- EPS
- AUPH 0.42
- CENTA 2.14
- Revenue
- AUPH $260,111,000.00
- CENTA $3,120,375,000.00
- Revenue This Year
- AUPH $17.33
- CENTA N/A
- Revenue Next Year
- AUPH $14.31
- CENTA $0.16
- P/E Ratio
- AUPH $31.33
- CENTA $13.14
- Revenue Growth
- AUPH 25.59
- CENTA N/A
- 52 Week Low
- AUPH $6.55
- CENTA $25.97
- 52 Week High
- AUPH $13.54
- CENTA $37.35
- Technical
- Relative Strength Index (RSI)
- AUPH 65.73
- CENTA 42.95
- Support Level
- AUPH $11.96
- CENTA $27.86
- Resistance Level
- AUPH $12.70
- CENTA $29.58
- Average True Range (ATR)
- AUPH 0.47
- CENTA 0.67
- MACD
- AUPH 0.17
- CENTA 0.18
- Stochastic Oscillator
- AUPH 85.96
- CENTA 50.65
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About CENTA Central Garden & Pet Company Nonvoting
Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.